<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2682</journal-id><journal-id journal-id-type="pmc-domain">cas</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Cancer Science</journal-title></journal-title-group><issn pub-type="ppub">1347-9032</issn><issn pub-type="epub">1349-7006</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11160026</article-id><article-id pub-id-type="pmcid-ver">PMC11160026.1</article-id><article-id pub-id-type="pmcaid">11160026</article-id><article-id pub-id-type="pmcaiid">11160026</article-id><article-id pub-id-type="pmid">18271941</article-id><article-id pub-id-type="doi">10.1111/j.1349-7006.2007.00700.x</article-id><article-id pub-id-type="publisher-id">CAS700</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Experimental Therapeutics and Clinical Medicine</subject></subj-group></subj-group></article-categories><title-group><article-title>Novel application of multicellular layers culture for <italic toggle="yes">in situ</italic> evaluation of cytotoxicity and penetration of paclitaxel</article-title></title-group><contrib-group><contrib id="cr1" contrib-type="author"><name name-style="western"><surname>Al&#8208;Abd</surname><given-names initials="AM">Ahmed Mohamed</given-names></name><xref rid="a1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cr2" contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="JH">Joo&#8208;Ho</given-names></name><xref rid="a1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cr3" contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="SY">So Yeon</given-names></name><xref rid="a2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cr4" contrib-type="author"><name name-style="western"><surname>Kun</surname><given-names initials="N">Na</given-names></name><xref rid="a3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cr5" contrib-type="author" corresp="yes"><name name-style="western"><surname>Kuh</surname><given-names initials="HJ">Hyo&#8208;Jeong</given-names></name><xref rid="a1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="a1">
<label>
<sup>1</sup>
</label>Department of Biomedical Sciences, College of Medicine, the Catholic University of Korea, Seoul 137&#8208;701;</aff><aff id="a2">
<label>
<sup>2</sup>
</label>Division of Engineering Education, College of Engineering, Chungnam National University, Daejeon 305&#8208;764;</aff><aff id="a3">
<label>
<sup>3</sup>
</label>Division of Biotechnology, the Catholic University of Korea, Bucheon 420&#8208;743, Korea</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
To whom correspondence should be addressed. E&#8208;mail: <email>hkuh@catholic.ac.kr</email></corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>2</month><year>2008</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2008</year></pub-date><volume>99</volume><issue seq="35">2</issue><issue-id pub-id-type="pmc-issue-id">464425</issue-id><issue-id pub-id-type="doi">10.1111/cas.2008.99.issue-2</issue-id><fpage>423</fpage><lpage>431</lpage><history>
(Received June 26, 2007/Revised October 24, 2007/Accepted October 24, 2007/Online publication February 4, 2008)</history><pub-history><event event-type="pmc-release"><date><day>06</day><month>02</month><year>2008</year></date></event><event event-type="pmc-live"><date><day>08</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-08 11:25:13.843"><day>08</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2008 Japanese Cancer Association</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CAS-99-423.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CAS-99-423.pdf"/><abstract><p>Limited drug penetration into tumor tissue is one of the major factors causing clinical drug resistance in human solid tumors. The multicellular layers (MCL) of human cancer cells have been successfully used to study tissue pharmacokinetics of anticancer drugs. The purpose of this study was to develop a direct and simple method to evaluate vitality changes <italic toggle="yes">in situ</italic> within MCL using calcein&#8208;AM. Human colorectal (DLD&#8208;1, HT&#8208;29) and bladder (HT&#8208;1376, J&#8208;82) cancer cells were grown in Transwell inserts to form MCL and subjected to paclitaxel exposure. The drug distribution was evaluated using paclitaxel&#8208;rhodamine. Photonic attenuation and limited penetration of calcein&#8208;AM prevented cellular vitality evaluation on optical sections under confocal microscopy in DLD&#8208;1 MCL. However, direct measurement of the fluorescence intensity on frozen sections of MCL allowed successful vitality assessment in more than 80% depth for HT&#8208;29 and J&#8208;82 MCL and in the upper 40% depth for DLD&#8208;1 and HT&#8208;1376 MCL. The penetration of paclitaxel&#8208;rhodamine was greater in HT&#8208;29 than DLD&#8208;1 and its distribution pattern was correlated to the spatial profile of vitality deterioration in both MCL, suggesting that tissue penetration may be an important determinant of drug effect in tumors. In conclusion, a novel method for vitality evaluation <italic toggle="yes">in situ</italic> within MCL was developed using calcein&#8208;AM. This method may provide clinically relevant data regarding the spatial pharmacodynamics of anticancer agents within avascular regions of solid tumors. (<italic toggle="yes">Cancer Sci</italic> 2008; 99: 423&#8211;431)</p></abstract><counts><fig-count count="7"/><table-count count="1"/><equation-count count="0"/><ref-count count="37"/><page-count count="9"/><word-count count="4845"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2008</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.4 mode:remove_FC converted:05.06.2024</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>